Icariin alleviates oxygen‐induced retinopathy by targeting microglia hexokinase 2
Immunology · 2024-09 · 173 (1) · 141-151
DOI: 10.1111/imm.13818 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, online erschienen am 28.05.2024. Verfasst von Xingran Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing, China. Hauptthemen laut MEDLINE: Flavonoids, Hexokinase, Microglia, Oxygen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes, Program for Youth Innovation in Future Medicine, Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology.
Abstract (Originalsprache)
Retinopathy of prematurity (ROP) is a retinal disease‐causing retinal neovascularization that can lead to blindness. Oxygen‐induced retinopathy (OIR) is a widely used ROP animal model. Icariin (ICA) has anti‐oxidative and anti‐inflammation properties; however, whether ICA has a regulatory effect on OIR remains unclear. In this study, ICA alleviated pathological neovascularization, microglial activation and blood–retina barrier (BRB) damage in vivo. Further results indicated that endothelial cell tube formation, migration and proliferation were restored by ICA treatment in vitro. Proteomic microarrays and molecular mimicry revealed that ICA can directly bind to hexokinase 2 (HK2) and decrease HK2 protein expression in vivo and in vitro. In addition, ICA inhibited the AKT/mTOR/HIF1α pathway activation. The effects of ICA on pathological neovascularization, microglial activation and BRB damage disappeared after HK2 overexpression in vivo. Similarly, the endothelial cell function was revised after HK2 overexpression. HK2 overexpression reversed ICA‐induced AKT/mTOR/HIF1α pathway inhibition in vivo and in vitro. Therefore, ICA prevented pathological angiogenesis in OIR in an HK2‐dependent manner, implicating ICA as a potential therapeutic agent for ROP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing, China.
- Department of Laboratory Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Beijing Tongren Eye Center, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing Tongren Hospital, Beijing Institute of Ophthalmology, Capital Medical University, Beijing, China.
ORCID-Profile: Shengping Hou
Förderung
- Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes
- Program for Youth Innovation in Future Medicine, Chongqing Medical University
- Chongqing Key Laboratory of Ophthalmology
- National Natural Science Foundation of China
Zitieren
APA
Li, X., Wang, G., Li, N., Wang, X., Fan, W., Zhang, Z., Li, W., Liu, J., Huang, J., Liu, X., Zhou, Q., & Hou, S. (2024). Icariin alleviates oxygen‐induced retinopathy by targeting microglia hexokinase 2. Immunology, 173(1), 141-151. https://doi.org/10.1111/imm.13818
Vancouver
Li X, Wang G, Li N, Wang X, Fan W, Zhang Z, et al. Icariin alleviates oxygen‐induced retinopathy by targeting microglia hexokinase 2. Immunology. 2024;173(1):141-151. doi:10.1111/imm.13818
BibTeX
@article{Li2024,
author = {Li, Xingran and Wang, Guoqing and Li, Na and Wang, Xiaotang and Fan, Wei and Zhang, Zhi and Li, Wanqian and Liu, Jiangyi and Huang, Jiaxing and Liu, Xianyang and Zhou, Qian and Hou, Shengping},
title = {Icariin alleviates oxygen‐induced retinopathy by targeting microglia hexokinase 2},
journal = {Immunology},
year = {2024},
volume = {173},
number = {1},
pages = {141--151},
doi = {10.1111/imm.13818}
}
EUVIMED